2020 Progressive Supranuclear Palsy Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Progressive Supranuclear Palsy pipeline report presents a comprehensive overview of the research and development of Progressive Supranuclear Palsy drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, five drugs in pre-clinical phase, seven drugs in Phase 1, four drugs in Phase 2, and one drug in Phase 3
As of February 2020, the Progressive Supranuclear Palsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Progressive Supranuclear Palsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha-synuclein inhibitors; Amyloid beta-protein precursor modulators; Antioxidants; Lipid peroxidation inhibitors; microtubule inhibitor; O-GlcNAcase inhibitor; Tau protein inhibitors; TauC3 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Progressive Supranuclear Palsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Progressive Supranuclear Palsy pipeline drugs profiled in the report include- ABBV-8E12, PBT434, AZP2006, tau protein for PSP, ASN120290, BIIB092 (gosuranemab), TPI287, Emeramide, TauC3 inhibitor for CNS Disorders, Stem Cell Therapy for Progressive Supranuclear Palsy, MK-8719, Tau inhibitor for PSP, RT001, LMTX (hydromethylthionine mesylate), UCB0107, Tau and alpha Synuclein program for PSP, Cellular Immunotherapy for Progressive Supranuclear Palsy, emeramide, TBL-100
As of February 2020, the Progressive Supranuclear Palsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Progressive Supranuclear Palsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha-synuclein inhibitors; Amyloid beta-protein precursor modulators; Antioxidants; Lipid peroxidation inhibitors; microtubule inhibitor; O-GlcNAcase inhibitor; Tau protein inhibitors; TauC3 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Progressive Supranuclear Palsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Progressive Supranuclear Palsy development
- Progressive Supranuclear Palsy pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Progressive Supranuclear Palsy pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Progressive Supranuclear Palsy pipeline candidates included
- Business overview and snapshot of all companies involved in Progressive Supranuclear Palsy pipeline are included
- Latest market and pipeline developments are provided in the report
Progressive Supranuclear Palsy pipeline drugs profiled in the report include- ABBV-8E12, PBT434, AZP2006, tau protein for PSP, ASN120290, BIIB092 (gosuranemab), TPI287, Emeramide, TauC3 inhibitor for CNS Disorders, Stem Cell Therapy for Progressive Supranuclear Palsy, MK-8719, Tau inhibitor for PSP, RT001, LMTX (hydromethylthionine mesylate), UCB0107, Tau and alpha Synuclein program for PSP, Cellular Immunotherapy for Progressive Supranuclear Palsy, emeramide, TBL-100
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Progressive Supranuclear Palsy Condition
2.3 Progressive Supranuclear Palsy Pipeline Snapshot, 2020
2.4 Companies investing in Progressive Supranuclear Palsy pipeline therapeutics
2.5 Phase wise Progressive Supranuclear Palsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Progressive Supranuclear Palsy Pipeline Products
2.7 Route of Administration of Progressive Supranuclear Palsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AbbVie Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Alterity Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 AlzProtect SAS Overview, Contacts and ASD Pipeline Drugs
3.4 Arvinas Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Asceneuron SA Overview, Contacts and ASD Pipeline Drugs
3.6 AZTherapies Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Cortice Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.9 EmeraMed Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Intellect Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.11 K-Stemcell Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.12 Merck & Co Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Prothena Corp Plc Overview, Contacts and ASD Pipeline Drugs
3.14 Retrotope Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Tau Bio-Logic Corp Overview, Contacts and ASD Pipeline Drugs
3.16 TauRx Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 UCB SA Overview, Contacts and ASD Pipeline Drugs
3.18 Voyager Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ABBV-8E12 Drug Details
4.1.1 ABBV-8E12 Current Status
4.1.2 ABBV-8E12 Drug Overview
4.1.3 ABBV-8E12 Mechanism of Action
4.1.4 ABBV-8E12 Licensing/Collaboration Companies
4.1.5 ABBV-8E12 Clinical Trials
4.2 PBT434 Drug Details
4.2.1 PBT434 Current Status
4.2.2 PBT434 Drug Overview
4.2.3 PBT434 Mechanism of Action
4.2.4 PBT434 Licensing/Collaboration Companies
4.2.5 PBT434 Clinical Trials
4.3 AZP2006 Drug Details
4.3.1 AZP2006 Current Status
4.3.2 AZP2006 Drug Overview
4.3.3 AZP2006 Mechanism of Action
4.3.4 AZP2006 Licensing/Collaboration Companies
4.3.5 AZP2006 Clinical Trials
4.4 tau protein for PSP Drug Details
4.4.1 tau protein for PSP Current Status
4.4.2 tau protein for PSP Drug Overview
4.4.3 tau protein for PSP Mechanism of Action
4.4.4 tau protein for PSP Licensing/Collaboration Companies
4.4.5 tau protein for PSP Clinical Trials
4.5 ASN120290 Drug Details
4.5.1 ASN120290 Current Status
4.5.2 ASN120290 Drug Overview
4.5.3 ASN120290 Mechanism of Action
4.5.4 ASN120290 Licensing/Collaboration Companies
4.5.5 ASN120290 Clinical Trials
4.6 BIIB092 (gosuranemab) Drug Details
4.6.1 BIIB092 (gosuranemab) Current Status
4.6.2 BIIB092 (gosuranemab) Drug Overview
4.6.3 BIIB092 (gosuranemab) Mechanism of Action
4.6.4 BIIB092 (gosuranemab) Licensing/Collaboration Companies
4.6.5 BIIB092 (gosuranemab) Clinical Trials
4.7 TPI287 Drug Details
4.7.1 TPI287 Current Status
4.7.2 TPI287 Drug Overview
4.7.3 TPI287 Mechanism of Action
4.7.4 TPI287 Licensing/Collaboration Companies
4.7.5 TPI287 Clinical Trials
4.8 Emeramide Drug Details
4.8.1 Emeramide Current Status
4.8.2 Emeramide Drug Overview
4.8.3 Emeramide Mechanism of Action
4.8.4 Emeramide Licensing/Collaboration Companies
4.8.5 Emeramide Clinical Trials
4.9 TauC3 inhibitor for CNS Disorders Drug Details
4.9.1 TauC3 inhibitor for CNS Disorders Current Status
4.9.2 TauC3 inhibitor for CNS Disorders Drug Overview
4.9.3 TauC3 inhibitor for CNS Disorders Mechanism of Action
4.9.4 TauC3 inhibitor for CNS Disorders Licensing/Collaboration Companies
4.9.5 TauC3 inhibitor for CNS Disorders Clinical Trials
4.10 Stem Cell Therapy for Progressive Supranuclear Palsy Drug Details
4.10.1 Stem Cell Therapy for Progressive Supranuclear Palsy Current Status
4.10.2 Stem Cell Therapy for Progressive Supranuclear Palsy Drug Overview
4.10.3 Stem Cell Therapy for Progressive Supranuclear Palsy Mechanism of Action
4.10.4 Stem Cell Therapy for Progressive Supranuclear Palsy Licensing/Collaboration Companies
4.10.5 Stem Cell Therapy for Progressive Supranuclear Palsy Clinical Trials
4.11 MK-8719 Drug Details
4.11.1 MK-8719 Current Status
4.11.2 MK-8719 Drug Overview
4.11.3 MK-8719 Mechanism of Action
4.11.4 MK-8719 Licensing/Collaboration Companies
4.11.5 MK-8719 Clinical Trials
4.12 Tau inhibitor for PSP Drug Details
4.12.1 Tau inhibitor for PSP Current Status
4.12.2 Tau inhibitor for PSP Drug Overview
4.12.3 Tau inhibitor for PSP Mechanism of Action
4.12.4 Tau inhibitor for PSP Licensing/Collaboration Companies
4.12.5 Tau inhibitor for PSP Clinical Trials
4.13 RT001 Drug Details
4.13.1 RT001 Current Status
4.13.2 RT001 Drug Overview
4.13.3 RT001 Mechanism of Action
4.13.4 RT001 Licensing/Collaboration Companies
4.13.5 RT001 Clinical Trials
4.14 LMTX (hydromethylthionine mesylate) Drug Details
4.14.1 LMTX (hydromethylthionine mesylate) Current Status
4.14.2 LMTX (hydromethylthionine mesylate) Drug Overview
4.14.3 LMTX (hydromethylthionine mesylate) Mechanism of Action
4.14.4 LMTX (hydromethylthionine mesylate) Licensing/Collaboration Companies
4.14.5 LMTX (hydromethylthionine mesylate) Clinical Trials
4.15 UCB0107 Drug Details
4.15.1 UCB0107 Current Status
4.15.2 UCB0107 Drug Overview
4.15.3 UCB0107 Mechanism of Action
4.15.4 UCB0107 Licensing/Collaboration Companies
4.15.5 UCB0107 Clinical Trials
4.16 Tau and alpha Synuclein program for PSP Drug Details
4.16.1 Tau and alpha Synuclein program for PSP Current Status
4.16.2 Tau and alpha Synuclein program for PSP Drug Overview
4.16.3 Tau and alpha Synuclein program for PSP Mechanism of Action
4.16.4 Tau and alpha Synuclein program for PSP Licensing/Collaboration Companies
4.16.5 Tau and alpha Synuclein program for PSP Clinical Trials
4.17 Cellular Immunotherapy for Progressive Supranuclear Palsy Drug Details
4.17.1 Cellular Immunotherapy for Progressive Supranuclear Palsy Current Status
4.17.2 Cellular Immunotherapy for Progressive Supranuclear Palsy Drug Overview
4.17.3 Cellular Immunotherapy for Progressive Supranuclear Palsy Mechanism of Action
4.17.4 Cellular Immunotherapy for Progressive Supranuclear Palsy Licensing/Collaboration Companies
4.17.5 Cellular Immunotherapy for Progressive Supranuclear Palsy Clinical Trials
4.18 emeramide Drug Details
4.18.1 emeramide Current Status
4.18.2 emeramide Drug Overview
4.18.3 emeramide Mechanism of Action
4.18.4 emeramide Licensing/Collaboration Companies
4.18.5 emeramide Clinical Trials
4.19 TBL-100 Drug Details
4.19.1 TBL-100 Current Status
4.19.2 TBL-100 Drug Overview
4.19.3 TBL-100 Mechanism of Action
4.19.4 TBL-100 Licensing/Collaboration Companies
4.19.5 TBL-100 Clinical Trials
5. LATEST PROGRESSIVE SUPRANUCLEAR PALSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Progressive Supranuclear Palsy Condition
2.3 Progressive Supranuclear Palsy Pipeline Snapshot, 2020
2.4 Companies investing in Progressive Supranuclear Palsy pipeline therapeutics
2.5 Phase wise Progressive Supranuclear Palsy Pipeline Candidates
2.6 Most Researched Mechanism of Action of Progressive Supranuclear Palsy Pipeline Products
2.7 Route of Administration of Progressive Supranuclear Palsy Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 AbbVie Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Alterity Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 AlzProtect SAS Overview, Contacts and ASD Pipeline Drugs
3.4 Arvinas Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Asceneuron SA Overview, Contacts and ASD Pipeline Drugs
3.6 AZTherapies Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Cortice Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.9 EmeraMed Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Intellect Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.11 K-Stemcell Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.12 Merck & Co Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Prothena Corp Plc Overview, Contacts and ASD Pipeline Drugs
3.14 Retrotope Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Tau Bio-Logic Corp Overview, Contacts and ASD Pipeline Drugs
3.16 TauRx Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 UCB SA Overview, Contacts and ASD Pipeline Drugs
3.18 Voyager Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ABBV-8E12 Drug Details
4.1.1 ABBV-8E12 Current Status
4.1.2 ABBV-8E12 Drug Overview
4.1.3 ABBV-8E12 Mechanism of Action
4.1.4 ABBV-8E12 Licensing/Collaboration Companies
4.1.5 ABBV-8E12 Clinical Trials
4.2 PBT434 Drug Details
4.2.1 PBT434 Current Status
4.2.2 PBT434 Drug Overview
4.2.3 PBT434 Mechanism of Action
4.2.4 PBT434 Licensing/Collaboration Companies
4.2.5 PBT434 Clinical Trials
4.3 AZP2006 Drug Details
4.3.1 AZP2006 Current Status
4.3.2 AZP2006 Drug Overview
4.3.3 AZP2006 Mechanism of Action
4.3.4 AZP2006 Licensing/Collaboration Companies
4.3.5 AZP2006 Clinical Trials
4.4 tau protein for PSP Drug Details
4.4.1 tau protein for PSP Current Status
4.4.2 tau protein for PSP Drug Overview
4.4.3 tau protein for PSP Mechanism of Action
4.4.4 tau protein for PSP Licensing/Collaboration Companies
4.4.5 tau protein for PSP Clinical Trials
4.5 ASN120290 Drug Details
4.5.1 ASN120290 Current Status
4.5.2 ASN120290 Drug Overview
4.5.3 ASN120290 Mechanism of Action
4.5.4 ASN120290 Licensing/Collaboration Companies
4.5.5 ASN120290 Clinical Trials
4.6 BIIB092 (gosuranemab) Drug Details
4.6.1 BIIB092 (gosuranemab) Current Status
4.6.2 BIIB092 (gosuranemab) Drug Overview
4.6.3 BIIB092 (gosuranemab) Mechanism of Action
4.6.4 BIIB092 (gosuranemab) Licensing/Collaboration Companies
4.6.5 BIIB092 (gosuranemab) Clinical Trials
4.7 TPI287 Drug Details
4.7.1 TPI287 Current Status
4.7.2 TPI287 Drug Overview
4.7.3 TPI287 Mechanism of Action
4.7.4 TPI287 Licensing/Collaboration Companies
4.7.5 TPI287 Clinical Trials
4.8 Emeramide Drug Details
4.8.1 Emeramide Current Status
4.8.2 Emeramide Drug Overview
4.8.3 Emeramide Mechanism of Action
4.8.4 Emeramide Licensing/Collaboration Companies
4.8.5 Emeramide Clinical Trials
4.9 TauC3 inhibitor for CNS Disorders Drug Details
4.9.1 TauC3 inhibitor for CNS Disorders Current Status
4.9.2 TauC3 inhibitor for CNS Disorders Drug Overview
4.9.3 TauC3 inhibitor for CNS Disorders Mechanism of Action
4.9.4 TauC3 inhibitor for CNS Disorders Licensing/Collaboration Companies
4.9.5 TauC3 inhibitor for CNS Disorders Clinical Trials
4.10 Stem Cell Therapy for Progressive Supranuclear Palsy Drug Details
4.10.1 Stem Cell Therapy for Progressive Supranuclear Palsy Current Status
4.10.2 Stem Cell Therapy for Progressive Supranuclear Palsy Drug Overview
4.10.3 Stem Cell Therapy for Progressive Supranuclear Palsy Mechanism of Action
4.10.4 Stem Cell Therapy for Progressive Supranuclear Palsy Licensing/Collaboration Companies
4.10.5 Stem Cell Therapy for Progressive Supranuclear Palsy Clinical Trials
4.11 MK-8719 Drug Details
4.11.1 MK-8719 Current Status
4.11.2 MK-8719 Drug Overview
4.11.3 MK-8719 Mechanism of Action
4.11.4 MK-8719 Licensing/Collaboration Companies
4.11.5 MK-8719 Clinical Trials
4.12 Tau inhibitor for PSP Drug Details
4.12.1 Tau inhibitor for PSP Current Status
4.12.2 Tau inhibitor for PSP Drug Overview
4.12.3 Tau inhibitor for PSP Mechanism of Action
4.12.4 Tau inhibitor for PSP Licensing/Collaboration Companies
4.12.5 Tau inhibitor for PSP Clinical Trials
4.13 RT001 Drug Details
4.13.1 RT001 Current Status
4.13.2 RT001 Drug Overview
4.13.3 RT001 Mechanism of Action
4.13.4 RT001 Licensing/Collaboration Companies
4.13.5 RT001 Clinical Trials
4.14 LMTX (hydromethylthionine mesylate) Drug Details
4.14.1 LMTX (hydromethylthionine mesylate) Current Status
4.14.2 LMTX (hydromethylthionine mesylate) Drug Overview
4.14.3 LMTX (hydromethylthionine mesylate) Mechanism of Action
4.14.4 LMTX (hydromethylthionine mesylate) Licensing/Collaboration Companies
4.14.5 LMTX (hydromethylthionine mesylate) Clinical Trials
4.15 UCB0107 Drug Details
4.15.1 UCB0107 Current Status
4.15.2 UCB0107 Drug Overview
4.15.3 UCB0107 Mechanism of Action
4.15.4 UCB0107 Licensing/Collaboration Companies
4.15.5 UCB0107 Clinical Trials
4.16 Tau and alpha Synuclein program for PSP Drug Details
4.16.1 Tau and alpha Synuclein program for PSP Current Status
4.16.2 Tau and alpha Synuclein program for PSP Drug Overview
4.16.3 Tau and alpha Synuclein program for PSP Mechanism of Action
4.16.4 Tau and alpha Synuclein program for PSP Licensing/Collaboration Companies
4.16.5 Tau and alpha Synuclein program for PSP Clinical Trials
4.17 Cellular Immunotherapy for Progressive Supranuclear Palsy Drug Details
4.17.1 Cellular Immunotherapy for Progressive Supranuclear Palsy Current Status
4.17.2 Cellular Immunotherapy for Progressive Supranuclear Palsy Drug Overview
4.17.3 Cellular Immunotherapy for Progressive Supranuclear Palsy Mechanism of Action
4.17.4 Cellular Immunotherapy for Progressive Supranuclear Palsy Licensing/Collaboration Companies
4.17.5 Cellular Immunotherapy for Progressive Supranuclear Palsy Clinical Trials
4.18 emeramide Drug Details
4.18.1 emeramide Current Status
4.18.2 emeramide Drug Overview
4.18.3 emeramide Mechanism of Action
4.18.4 emeramide Licensing/Collaboration Companies
4.18.5 emeramide Clinical Trials
4.19 TBL-100 Drug Details
4.19.1 TBL-100 Current Status
4.19.2 TBL-100 Drug Overview
4.19.3 TBL-100 Mechanism of Action
4.19.4 TBL-100 Licensing/Collaboration Companies
4.19.5 TBL-100 Clinical Trials
5. LATEST PROGRESSIVE SUPRANUCLEAR PALSY PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
